Selvita vs WuXi AppTec

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/selvita/wuxiapptec

Category	Selvita	WuXi AppTec
Listed site	cro	cro
Summary	Selvita is an integrated drug discovery and development CRO offering comprehensive services from target validation through preclinical candidate nomination, with expertise in small molecules, antibodies, and protein degraders, plus GMP/GLP-compliant development and manufacturing support.	Global CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Services	Bioinformatics & Data Science Computational & In-Silico Drug Discovery Medicinal Chemistry High-Throughput Screening Target Identification & Validation Discovery Research In Vitro Pharmacology In Vitro ADME / DMPK Preclinical In Vitro Studies In Vivo PK / PD Studies In Vivo Efficacy Models Preclinical In Vivo Studies Analytical Method Development & Validation ICH Stability Studies Regulatory Affairs Bioanalysis LC-MS Bioanalysis (Small Molecule)	Discovery Research Target Identification & Validation High-Throughput Screening Medicinal Chemistry Computational & In-Silico Drug Discovery Protein Engineering Preclinical In Vitro Studies In Vitro Pharmacology In Vitro ADME / DMPK Safety Pharmacology Genetic Toxicology Preclinical In Vivo Studies In Vivo Efficacy Models In Vivo PK / PD Studies GLP Toxicology Carcinogenicity Studies DART (Reproductive & Developmental Toxicology) Specialized & Large-Animal Models Bioanalysis LC-MS Bioanalysis (Small Molecule) Ligand-Binding Bioanalysis (Large Molecule) Immunogenicity Assays (ADA / NAb) Biomarker Assays Flow Cytometry Services Clinical Trial Services Phase I Clinical Trials Phase II Clinical Trials Phase III Clinical Trials Phase IV / Post-Marketing Data Management & eClinical Biostatistics & Statistical Programming Medical Writing Pharmacovigilance & Drug Safety Regulatory Affairs US FDA Regulatory Strategy EU EMA Regulatory Strategy Japan PMDA Regulatory Strategy China NMPA Regulatory Strategy Analytical Method Development & Validation ICH Stability Studies Translational Research
Modalities	Small Molecule Biologics (Monoclonal Antibodies) Peptide	Small Molecule Peptide Oligonucleotide Biologics (Monoclonal Antibodies) Biologics (Other) Antibody-Drug Conjugate (ADC) mRNA Cell Therapy Gene Therapy Vaccine
Indications	Oncology Respiratory Neurology Metabolic Infectious Disease Gastroenterology Immunology	Oncology Immunology Neurology Psychiatry Metabolic Cardiovascular Infectious Disease Rare Disease Respiratory Dermatology Ophthalmology Gastroenterology Nephrology Women's Health
Locations	Data not yet provided.	Headquarters, Shanghai, Pudong, China Global Operations, Asia, Europe, North America
Certifications	Data not yet provided.	Data not yet provided.
Reviews	Review summary appears after site-level review signal gate opens.	Review summary appears after site-level review signal gate opens.